Cite

HARVARD Citation

    Deva, S. et al. (n.d.). 70OA phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors. Annals of oncology. p. . [Online]. 
  
Back to record